North America Biologics Safety Testing Market Size, Share & Forecast (2025-2035)
The North America Biologics Safety Testing Market has experienced substantial growth, driven by rising demand for biologics including vaccines, gene therapies, and cell therapies due to increasing prevalence of chronic and infectious diseases. Innovative technologies in biologics testing are supporting the flow of safer products to market, with regulatory bodies emphasizing robust safety assessment. The market is broadly segmented by type, application, distribution channel, technology, and organization size, covering leading industry players offering advanced kits, services, and instruments across the region.
Latest Market Dynamics
Key Drivers
- Rising Adoption of Biologics in Therapeutics: The growth in demand for biologics, including monoclonal antibodies and gene therapies, is driving the need for advanced safety testing solutions. In June 2024, Thermo Fisher Scientific expanded its biologics safety portfolio to meet increased requirements for vaccine and cell therapy manufacturing.
- Stringent Regulatory Guidelines for Biologics Safety: The enforcement of strict FDA and Health Canada regulations toward biologics safety testing is supporting market growth. Companies like Charles River Laboratories have recently introduced new compliance-driven safety testing services for North America in 2024.
Key Trends
- Integration of High-Throughput Testing and Automation: Recent trends highlight an increased focus on automated high-throughput safety testing for biologics manufacturers. Merck KGaA incorporated advanced automation platforms for rapid endotoxin and mycoplasma testing in May 2024.
- Outsourcing of Safety Testing Services: Outsourcing biologics safety testing is on the rise as companies look for efficiency and cost savings. Eurofins Scientific’s June 2024 partnership with regional pharmaceutical manufacturers underscores this shift.
Key Opportunities
- Expansion of Cellular and Gene Therapy Applications: The burgeoning field of gene and cell therapies offers significant opportunities for safety testing, especially with regulatory approvals accelerating. In July 2024, Lonza Group announced investments in new safety testing facilities dedicated to advanced therapies.
- Adoption of Next-Generation Sequencing (NGS) in Safety Testing: Implementing NGS technology offers enhanced sensitivity and specificity for contaminant detection. Danaher Corporation launched NGS-based safety solutions for biologics quality control in August 2024.
Key Challenges
- Complexity and Cost of Advanced Testing Technologies: The high cost and operational complexity of implementing solutions like NGS and cell-based assays pose challenges, particularly to medium-sized organizations. Smaller market entrants reportedly face barriers despite growing demand in June 2024.
- Regulatory Uncertainties for New Modalities: Rapid advancements in biotherapeutics often outpace regulatory guidance, leading to uncertainty in compliance. In July 2024, several North American cell therapy start-ups highlighted ongoing navigation around emerging regulatory standards.
Key Restraints
- Limited Skilled Workforce: The shortage of expertise in advanced biologics safety technologies remains a bottleneck for market scaling. By mid-2024, companies including Sartorius AG emphasized broadening workforce training programs.
- High Initial Investment: The need for significant upfront investment in equipment and compliance processes can limit adoption by smaller organizations. This was noted in reports from Promega Corporation in June 2024.
Market Share by Type, 2025
In 2025, Kits & Reagents capture the largest share of the North America Biologics Safety Testing Market, accounting for 48%, driven by their widespread application and requirement for recurring consumables. Services follow with a share of 28%, reflecting the push toward outsourcing analytical and compliance operations. Instruments account for 14%, while consumables and software together contribute 7%, and others 3%. The dominance of kits and reagents highlights the high frequency of testing required in biologics manufacturing pipelines.
Market Share by Application, 2025
Vaccines & Therapeutics represent the largest application segment in 2025 with 41% market share, reflecting the ongoing need for safety testing across these high-volume biopharma products. Cellular & Gene Therapy is growing rapidly, holding 25%, demonstrating the expanding pipeline for advanced therapies. Blood Products account for 13%, while Tissue Products and Stem Cell Products collectively contribute 15%, and others 6%. This distribution underscores strong momentum in innovative treatment areas fueling market expansion.
North America Biologics Safety Testing Market Revenue (USD Million), 2020-2035
The North America Biologics Safety Testing Market revenue has shown a consistent rise from 2020 through 2025, with the market estimated to reach USD 2,150 Million in 2025. Growth projections indicate the market will surpass USD 4,960 Million by 2035. Major contributing factors include growing investments in advanced biologics research, shifting disease burden, and strong regulatory emphasis on product safety. Steady growth reflects increasing adoption across traditional and novel therapeutic classes.
North America Biologics Safety Testing Market YOY Growth Rate (%), 2020-2035
Year-over-year growth for the North America Biologics Safety Testing Market remained robust through the forecast period, averaging 8.2% during 2020-2025, plateauing slightly to 7.8% by 2030, and then moderating to 6.2% by 2035 as the market approaches maturity. The highest surge is attributed to waves of biologics approval and market entry during 2024-2027, driven by policy reform and new technological rollouts.
Market Share by Region, 2025
In 2025, the US maintains the largest share of the North America Biologics Safety Testing Market at 74%, leveraging strong biopharma infrastructure, industry presence, and regulatory frameworks. Canada holds an 18% share due to growing biologics investments and government support for innovation. Mexico captures 8%, reflecting rising healthcare industry modernization. The disparities highlight the continued dominance of the US while countries like Canada and Mexico offer incremental potential.
Market Players Share, 2025
Thermo Fisher Scientific leads the North America biologics safety testing market with a 19% share in 2025, supported by its expansive portfolio and frequent new product launches. Merck KGaA and Charles River Laboratories follow closely with 13% and 10% each, owing to their global reach and compliance-driven service offerings. Eurofins Scientific, SGS SA, Lonza, Sartorius, WuXi AppTec, and others collectively constitute the remaining 58%, highlighting a moderately consolidated competitive landscape.
Market Buyers Share, 2025
In 2025, pharmaceutical and biotechnology companies dominate as principal buyers representing 66% of total market demand, reflecting sustained investment in safety-compliant product pipelines. Research institutes and hospitals follow with a combined 22%, as adoption of advanced testing enters clinical research and healthcare arenas. Contract Research Organizations (CROs) and academic labs constitute the remaining 12%, signifying growing outsourcing and partnership trends in safety testing.
Study Coverage
| Metrics | Details |
|---|
| Years | 2020-2035 |
| Base Year | 2025 |
| Market Size | 2150 |
| Regions | US, Canada, Mexico |
| Segments | By Type: Kits & Reagents, Services, Instruments, Consumables, Software, Others; By Application: Vaccines & Therapeutics, Blood Products, Cellular & Gene Therapy, Tissue & Tissue Products, Stem Cell Products, Others; By Distribution Channels: Direct Sales, Distributors, Online Sales, Retail Pharmacies, Hospitals, Others; By Technology: PCR, ELISA, Cell Culture, High-Throughput Sequencing, Immunoassays, Others; By Organization Size: Small, Medium, Large |
| Players | Thermo Fisher Scientific, Merck KGaA, Charles River Laboratories, Eurofins Scientific, SGS SA, Lonza Group, Sartorius AG, WuXi AppTec, Promega Corporation, Toxikon Corporation, Danaher Corporation, Bio-Rad Laboratories, GenScript Biotech Corporation, Fujifilm Diosynth Biotechnologies, Avance Biosciences |
Key Recent Developments
- July 2024: Lonza Group unveils $120 million investment in North American safety testing facility focused on cell and gene therapy.
- June 2024: Eurofins Scientific signs new contract with top US biologics manufacturer to expand outsourced safety testing services.
- August 2024: Danaher Corporation launches next-generation NGS-based biologics safety testing platform for the North American market.
- June 2024: Thermo Fisher Scientific introduces rapid endotoxin and sterility testing kits tailored for vaccine producers.
- July 2024: Merck KGaA debuts automated, high-throughput safety testing solution for commercial biomanufacturers in the US and Canada.
